European Patent rights covering use of HSP70 for the treatment of lysosomal storage diseases registered in 21 European countries
Orphazyme ApS today announced that the recently granted European Patent No. EP 2 318 032 B1 has taken effect in 21 countries across Europe, including United Kingdom, Germany and France.
Orphazyme develops therapies for the treatment of genetic disorders. The lead program is in preclinical development for the treatment of lysosomal storage diseases. Currently, only few treatment options exist for this family of serious genetic disorders, of which most are currently untreatable and often fatal, thus representing a significant unmet medical need. Orphazyme has applied its discovery capabilities to building a proprietary platform used for a novel and paradigm-changing approach to developing new treatments for these serious diseases.
The granted European Patent covers broadly the use of HSP70 for the treatment of lysosomal storage diseases including Gaucher, Fabry, Niemann-Pick and Krabbe disease.
Anders Hinsby, CEO of Orphazyme, says: "The grant of the European Patent is a major milestone for the company; it validates the very high innovative level of our technology and positions us well to further develop heat-shock protein based therapeutics for the treatment of lysosomal storage diseases."
Anders Hinsby, CEO of Orphazyme
Orphazyme ApS is a Danish biopharmaceutical company, which develops paradigm-changing medicines for the treatment of genetic diseases. The lead program is in preclinical development as treatment for lysosomal storage diseases. This family of genetic disorders consists of more than 45 diseases, most of which are currently untreatable and often fatal. Orphazyme has raised more than 17 million euro in seed and series A financing, from a strong investor base which includes Novo Ventures, Sunstone Capital and Aescap Venture. For more information, please visit www.orphazyme.com.